Viropharma acquires Swedish orphan drug firm DuoCort
This article was originally published in Scrip
ViroPharma, an Exton, Pennsylvania-based firm whose products include treatments for the rare genetic disorder hereditary angioedema (HAE) and for GI infections caused by Staphylococcus aureus and Clostridium difficile, has agreed to pay up to around $165 million to acquire DuoCort Pharma, the Swedish firm awaiting European approval for a drug to treat the rare condition Addison's disease and other conditions causing adrenal insufficiency in adults.
You may also be interested in...
AbbVie’s Humira has been the world’s best-selling drug since 2012, and if it hadn’t been for COVID-19 it would most likely have been on track to retain its position for the 10th year in row.
From the latest COVID-19 advances to the emergence of a game changer for heart failure, Scrip’s editor in chief Eleanor Malone reviews the big stories of the past three months. Safety issues around JAK inhibitors and AAV vector-based gene therapy were also to the fore, while biopharma financing continued apace.
A snapshot of the compensation packages of CEOs and R&D leaders of the world’s biggest pharmaceutical companies, alongside median employee pay and key company performance metrics.